Hormonal
Intermittent administration of the senolytic drug combination dasatinib and quercetin (D&Q) reduces senescence and inflammation in adipose tissue, leading to improved systemic metabolic function (fasting glucose, glucose tolerance, and lipid profiles) in old age.
For older adults, intermittent treatment with dasatinib and quercetin may improve metabolic health by clearing senescent cells from fat tissue, reducing inflammation, and improving glucose tolerance. This suggests that targeting cellular aging could be a viable strategy for managing age-related metabolic decline.
Collectively, results from this study suggest that D&Q attenuates adipose tissue inflammation and improves systemic metabolic function in old age.
Why this rating
Randomized controlled trial in mice with robust statistical significance (p <= 0.04 for most markers) and multiple metabolic tests.
Source
Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age
Md Torikul Islam et al. · Aging Cell · 2023
DOI 10.1111/acel.13767
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →